Brendan R. Haberle

San Diego
  • 12670 High Bluff Drive
  • San Diego, CA 92130
  • USA
 
 

Brendan Haberle’s practice focuses on technology transactions, primarily within the life sciences industry.

Mr. Haberle advises companies on technology licensing and intellectual property portfolio management, as well as regarding intellectual property concerns within corporate transactions such as public offerings and mergers and acquisitions.

Mr. Haberle also has experience representing startup and emerging growth companies in many industries on early stage matters such as formation, fund raising, and corporate governance.

Prior to joining the firm, Mr. Haberle supported the Intelligence Community’s counter-proliferation and counter-terrorism missions, deploying to Iraq and Afghanistan.

While in law school, Mr. Haberle served on the Arizona Law Review and as Co-President of the Arizona Intellectual Property and Cyberlaw Society.

Mr. Haberle’s recent transactions include:

  • Ignyta, Inc. in its US$1.7 billion merger with Roche
  • Impact Biomedicines in its acquisition by Celgene for up to
    US$7 billion
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.